Iterum Therapeutics plc (ITRM)
NASDAQ: ITRM · Real-Time Price · USD
1.490
0.00 (0.00%)
At close: Feb 21, 2025, 4:00 PM
1.520
+0.030 (2.01%)
After-hours: Feb 21, 2025, 5:56 PM EST
Iterum Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
9
Market Cap
51.53M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ITRM News
- 16 days ago - Iterum Therapeutics plc (ITRM) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 16 days ago - Iterum Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 23 days ago - Iterum Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 7, 2025 - GlobeNewsWire
- 3 months ago - Iterum Therapeutics Regains Full Nasdaq Compliance - GlobeNewsWire
- 3 months ago - Iterum Therapeutics plc (ITRM) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Iterum Therapeutics Reports Third Quarter 2024 Financial Results - GlobeNewsWire
- 4 months ago - Iterum Therapeutics plc (ITRM) U.S. FDA Approval of ORLYNVAH Call (Transcript) - Seeking Alpha
- 4 months ago - Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections - PRNewsWire